Elevance Health (ELV) closed the latest trading day at $510.57, indicating a +0.21% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.29% for the day. Meanwhile, the Dow experienced a drop of 0.35%, and the technology-dominated Nasdaq saw a decrease of 0.3%.The health insurer's stock has climbed by 0.67% in the past month, falling short of the Medical sector's gain of 3.72% and the S&P 500's gain of 4.42%.The investment community will be closely monitoring ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Elevance Health (ELV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Elevance Health currently has an average brokerage recomm ...

Elevance Health, Inc. (ELV) recently announced that it has completed the acquisition of Paragon Healthcare, Inc., the agreement for which was made public in the first week of this year. The strategic move is aimed at boosting its capabilities in multi-site infusion services and specialty pharmacy.Earlier, Reuters reported that the acquisition would cost ELV more than $1 billion, according to an Axios report. The acquisition is expected to help the company offer affordable and convenient healthcare solutions ...

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the closing of its acquisition of Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. Paragon Healthcare provides infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, currently serves more than 35,000 patients at over 40 a ...

nortonrsx/iStock via Getty Images Elevance Health, Inc. (NYSE:ELV) reported strong financial growth in Q4 and full year 2023 with the increase in revenues and earnings per share. This growth was driven by the uptick in premium and product revenues. The company also showed growth in net income in 2023, despite the increase in total expenses. This article presents the financial metrics of Elevance Health, strategic contribution of different segments and technical analysis based on the historical trends. I ...

Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings ...

It has been about a month since the last earnings report for Elevance Health (ELV) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Elevance Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Elevance Health Q4 Earnings Beat on Pr ...

Elevance Health (ELV) closed the latest trading day at $512.17, indicating a +0.55% change from the previous session's end. This move lagged the S&P 500's daily gain of 2.11%. On the other hand, the Dow registered a gain of 1.18%, and the technology-centric Nasdaq increased by 2.96%.The health insurer's stock has climbed by 7.54% in the past month, exceeding the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.Analysts and investors alike will be keeping a close eye on the performance of Eleva ...

Revenue and Membership - Approximately 29% of total consolidated revenues were generated from U.S. government agencies for the year ended December 31, 2023, compared to 28% in 2022 and 2021[25]. - The company expects growth in Public Exchange membership for 2024, expanding offerings in 141 of the 143 rating regions, up from 138 in 2023[33]. - The company is experiencing a decline in Medicaid membership due to the resumption of eligibility redeterminations, which began on April 1, 2023, and is expected to complete by June 30, 2024[79]. - The company anticipates a reduction in its 2025 operating revenue of approximately $500 million due to changes in Medicare Advantage Star ratings, with 34% of members in plans rated at least 4.0 Stars for 2024, down from 64% for 2023[87]. - The company is expanding its participation in Individual Public Exchange products, offering them in 141 of the 143 rating regions for 2024, compared to 138 regions in 2023[87]. Business Segments and Services - The company reorganized its reportable segments in the first quarter of 2023, which includes Commercial & Specialty Business, Government Business, CarelonRx, and Other[26]. - The Health Benefits segment offers a comprehensive suite of health plans and services, including risk-based and fee-based products, catering to various customer types such as Individual, Employer Group, Medicare, and Medicaid[27]. - CarelonRx, the pharmacy services subsidiary, provides a comprehensive portfolio including home delivery, specialty pharmacies, and pharmacy benefit management services[40]. - Carelon Services integrates physical, behavioral, social, and pharmacy services, enhancing healthcare delivery through analytics and competitive service offerings[29]. - The company’s Carelon Health subsidiary focuses on whole-person care for members with complex conditions, enhancing clinical outcomes and patient well-being[65]. Competitive Landscape - The managed care industry remains highly competitive, with intense competition driven by aggressive marketing, pricing, and technological advancements[42]. - The company maintains a competitive unit cost position through its provider networks, which are built by securing favorable contracts with healthcare providers[48]. - The pricing strategy for health benefit products is based on predictive modeling and aims to remain competitive while anticipating underlying medical trends[47]. Operational Efficiency and Technology - The company aims to improve customer interactions through digital technology and operational enhancements, optimizing administrative costs while improving service quality[24]. - The company leverages data and analytics to improve healthcare outcomes and lower costs, ensuring timely and accurate reimbursement for providers[44]. - The company has expanded its integrated care management programs, including the digital engagement platform Sydney Health, to improve member access to health resources[65]. - The company’s medical management programs are designed to ensure timely, evidence-based care, with a focus on improving quality and reducing costs[62]. Regulatory Compliance and Financial Health - The company is subject to comprehensive state, federal, and international regulations that impact its operations and may result in additional costs[75]. - The company is required to comply with various BCBSA license agreement standards, including maintaining at least 80% of annual combined local net revenue under the BCBS names and marks[73]. - The Health Plan Transparency Rule requires the company to disclose detailed pricing information on a monthly basis, starting from July 2022[99]. - Effective January 1, 2024, the requirement to provide personalized out-of-pocket cost information will expand to include all items and services[99]. - As of December 31, 2023, the RBC levels of the company's insurance and HMO subsidiaries exceeded all applicable mandatory RBC requirements[84]. Financial Performance - Cash provided by operating activities decreased to $8,061 million in 2023 from $8,399 million in 2022, a decline of $338 million[344]. - Total sources of cash decreased to $8,839 million in 2023 from $10,205 million in 2022, a decrease of $1,366 million[344]. - Total uses of cash increased to $9,699 million in 2023 from $7,684 million in 2022, an increase of $2,015 million[344]. - Cash, cash equivalents, and investments in fixed maturity and equity securities increased to $37,245 million as of December 31, 2023, up by $2,201 million from the previous year[348]. - The consolidated debt-to-capital ratio improved to 38.9% as of December 31, 2023, down from 39.9% in 2022[352]. Employee Engagement and Diversity - As of December 31, 2023, the employee population consisted of approximately 104,900 individuals, with 78,100 in the United States and 26,800 internationally[103]. - More than 90% of associates participated in the 2023 internal engagement survey, indicating strong employee involvement[105]. - The company invested an average of approximately 28 hours of training and development per associate in 2023[109]. - The U.S. associate population was approximately 77% female and 50% racially and ethnically diverse as of December 31, 2023[107]. - Pay for females in the U.S. is within 1% of their male counterparts, and pay for people of color is equal to their white counterparts after accounting for job-related factors[108]. Future Outlook and Strategic Initiatives - The company has authorized a common stock repurchase program of $4,200, with no specified duration[366]. - The company expects to receive approximately $4,400 in dividends from subsidiaries during 2024, compared to $4,909 received in 2023[360]. - Future debt and estimated interest payments total $40,491, with $2,661 due within the next twelve months[368]. - The company believes that cash on hand, operating cash receipts, and available credit facilities will be sufficient to fund expected cash disbursements over the next twelve months[362].

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Elevance Health (ELV) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Elevance Health is a member of the Medical sector. This group includes 1069 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 1 ...